Houston, Texas — Genialis and Inventia Life Science have formed a collaboration to combine artificial intelligence-driven patient data with 3D pancreatic cancer models to support drug development and patient selection.
The companies will pair the Genialis Supermodel with Inventia’s RASTRUM 3D cell model platform to create models of pancreatic ductal adenocarcinoma that reflect the tumor biology of identifiable patient groups.
Genialis uses its Supermodel, a large molecular model trained on a proprietary transcriptomics dataset, to characterize molecular states seen in patient tumors. Inventia’s RASTRUM platform creates reproducible 3D cancer models in which tumor and stromal components can be independently controlled and studied.
The collaboration is designed to allow researchers to derive therapeutic hypotheses from patient data, test them experimentally in human-relevant models and then determine which patient populations may be most likely to benefit.
In a study being presented at the Pancreatic Cancer Action Network’s 2026 Scientific Summit, Genialis analyzed 644 pancreatic cancer tumors from the PanCAN SPARK “Know Your Tumor” cohort and identified patients with poor prognosis based on the composition and activity of the tumor microenvironment.
Researchers then mapped those patient profiles to tumor-fibroblast co-culture models generated using RASTRUM, allowing them to investigate biological features associated with poor outcomes and test potential therapeutic approaches.
“This collaboration closes an important gap in drug discovery by connecting what we learn from patients with what we can test in the lab,” said Cameron Ferris, Ph.D., Chief Executive Officer and Co-Founder of Inventia Life Science. “Genialis can identify clinically meaningful biological states in real tumors, while RASTRUM allows us to model and perturb those states at scale. Together, that creates a powerful way to generate and test therapeutic hypotheses that are grounded in the biology of the patients we ultimately want to treat.”
Rafael Rosengarten, Ph.D., Chief Executive Officer and Co-Founder of Genialis, said the approach could help pharmaceutical companies make earlier decisions about patient enrollment and potential drug combinations.
“Our pharma partners need to make critical decisions about which patients to enroll and which combinations to pursue, yet historically, whether a preclinical result would translate to patients often wasn’t clear until Phase 2,” Rosengarten said. “Inventia gives us a model where we can test those hypotheses experimentally, while the Supermodel helps identify the patients most likely to benefit.”
Genialis develops AI-powered therapeutic intelligence tools, while Inventia Life Science develops 3D cell modeling technology for biomedical research.
